title: Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine-glutamate interactions.
authors.forename: M G
authors.initials: MG
authors.lastname: Brunstein
authors.forename: P
authors.initials: P
authors.lastname: Belmonte-de-Abreu
authors.forename: D O
authors.initials: DO
authors.lastname: Souza
authors.forename: D R
authors.initials: DR
authors.lastname: Lara
mesh_terms: D000241:Adenosine / Q000378:metabolism; D004176:Dipyridamole / Q000494:pharmacology*; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D010726:Phosphodiesterase Inhibitors; D017448:Receptors, Dopamine D2; D018698:Glutamic Acid; D004176:Dipyridamole; D000241:Adenosine